Biotech Elevian announces $15m equity financing

Elevian announced this week it closed $15 million, allowing it to advance recombinant growth differentiation factor 11 (rGDF11)

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The anti-aging company looks to the clinic with Prime Movers Lab leading the round.

Massachusets-based Elevian announced this week that it had closed $15 million equity financing, allowing it to advance recombinant growth differentiation factor 11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2142

Elevian

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Elevian is a clinical-stage biopharmaceutical company developing recombinant protein therapeutics designed to restore regenerative capacity and address age-related diseases. The company's lead program, rGDF11, targets stroke recovery and has demonstrated efficacy in preclinical models of cardiovascular, neurological, metabolic, and inflammatory conditions. Elevian's approach leverages circulating growth factors discovered at Harvard to promote neovascularization, neurogenesis, and tissue repair. The company aims to transform treatment paradigms for acute neurological injuries and chronic age-related pathologies by targeting fundamental mechanisms of aging and regenerative decline.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE